| Drug name | PC-BISAB-011 |
| Overview | PC-BISAB-011 is a bispecific human monoclonal IgG1 antibody targeting human B cell maturation antigen (BCMA) and CD3. It induced selective lysis of BCMA-positive multiple myeloma cells, activation of T cells, release of cytokines and T-cell proliferation. |
| Target | The CD3 antigen is a protein complex composed of four distinct chains: CD3 gamma chain, CD3 delta chain and two CD3epsilon chains. Association of the CD3 chains with TCR and the zeta-chain (accessory molecules of TCR) generates an activation signal in T lymphocytes. The CD3/TCR complex regulates the infiltration of the cytotoxic T lymphocytes into the tumor cells, so that cytotoxic T lymphocytes provoke changes in tumor cells and subsequently induce cell death. BCMA is a highly plasma cell specific antigen which has a central role in regulating B-cell maturation and differentiation into plasma cells by engaging a proliferation inducing ligand (APRIL), and is required for optimal survival of long-lived plasma cells in the bone marrow. BCMA that expressed on multiple myeloma cell lines and malignant plasma cells with high prevalence and increased expression levels is an ideal target for T-cell redirecting therapies. |
| Indication | Multiple myeloma is the most common hematologic malignancy in the adult population, accounting for approximately 10-13% of all hematologic malignancies. According to Globocan, the age-standardized incidence rate on a global scale is 1.5 per 100,000. |